Best practices for rapid test development and regulatory approvals.
Using anatomic pathology for biomarker development in clinical trials can help predict and assess how a patient will respond to immuno-oncology therapies
Measurement of Residual Disease for improved oncology trial outcomes - what factors make an MRD test most effective plus explore the pros and cons of various MRD measurement approaches.
Exploring the challenges with the diverse clinical biomarker requirements.
Advances in precision medicine lead to new trends in immunotherapy.
Overcoming hurdles in a regulated setting.
CRO mergers affect the agility and speed of operations and may hamper efforts to bring in new technologies but at the same time can add significant value to both the pharmaceutical industry and the patients who depend on the life-saving medicines it produces.
Best practices to ensure a successful sponsor-CRO collaboration
Applying lessons learned to the future of Immuno-oncology.
CROs & Sponsors: Have we overcome the limitations of early site payment solutions? Learn how a Site Payment Advisory Group helped improve site payment technology for all stakeholders.
|
|
|
|
|
|
|
|
|